A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma

Blood

Volumn 91, Issue 12, 1998, Pages 4727-4737

  Rebouissou, Cosette ^b   Wijdenes, John ^b   Autissier, Patrick ^b   Tarte, Karin ^b   Costes, Valerie ^b   Liautard, Janny ^b   Rossi, Jean Francois ^b   Brochier, Jean ^b   Klein, Bernard ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; PHENOTYPE; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; SCID MOUSE; SOLID TUMOR; TRANSDUCER; TUMOR CELL CULTURE;

EID: 0031839962     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.12.4727.412k35_4727_4737     Document Type: Article

References (49)

1. Feo-Zuppardi FJ, Taylor CW, Iwato K, Lopez MH, Grogan TM, Odeleye A, Hersh EM, Salmon SE: Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 80:2843, 1992
2. Ahsmann EJ, van Tol MJ, Oudeman-Gruber J, Lokhorst H, Uytdehaag FG, Schuurman HJ, Bloem AC: The SCID mouse as a model for multiple myeloma. Br J Haematol 89:319, 1995
3. Alsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR, Roodman GD: Development of an in vivo model of human multiple myeloma bone disease. Blood 87:1495, 1996
4. Pellat Deceunynk C, Amiot M, Bataille R, Van Riet I, Van Camp B, Omede P, Boccadoro M: Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after [letter]. Blood 86:4001, 1995
5. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC: The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90:754, 1997
6. Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, Goto H, Shimazaki C, Nakagawa M, Ohsugi Y, Kishimoto T, Akamatsu K: New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 90:2437, 1997
7. Klein B, Zhang XG, Lu ZY, Bataille R: Interleukin-6 in human multiple myeloma. Blood 85:863, 1995
8. Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T: Myeloma biology and therapy. Present status and future developments. Hematol Oncol Clin North Am 11:159, 1997
9. van Dam M, Mullberg J, Schooltink H, Stoyan T, Brakenhoff JP, Graeve L, Heinrich PC, Rose-John S: Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem 268:15285, 1993
10. Montero-Julian FA, Klein B, Gautherot E, Brailly H: Pharmacokinetic study of anti-IL-6 therapy with monoclonal antibodies: Enhancement of IL-6 clearance by a cocktail of anti-IL-6 antibodies. Blood 85:917, 1995
11. Castell JV, Geiger T, Andus T, Walter E, Hirano T, Kishimoto T, Heinrich PC: Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 177:357, 1988
12. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 11:443, 1990
13. Delamata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD: Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 95:2846, 1995
14. Sakata Y, Morimoto A, Long NC, Murakami N: Fever and acute phase response induced in rabbits by intravenous and intracerebroventricular injection of interleukin-6. Cytokine 3:199, 1991
15. Wijdenes J, Heinrich PC, Muller Newen G, Roche C, Gu ZJ, Clement C, Klein B: Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol 25:3474, 1995
16. Autissier P, Liautard J, Brochier J, Gaillard JP: Activation of the gp130 signaling pathway by monoclonal antibodies directed against the gp130 molecule. Eur J Immunol 27:794, 1997
17. Horvathova M, Gaillard JP, Liautard J, Duperray C, Lavabre-Bertrand T, Bourquard P, Rossi JF, Klein B, Brochier J: Identification of novel and specific antigens of human plasma cells by mAb, in Schlossman SF, Boumsell L, Gilks W, Harlan JM. Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF (eds): Leucocyte Typing V, London, UK, Oxford, 1995, p 713
18. Liautard J, Gaillard JP, Mani JC, Montera Julian F, Duperray C, Lu ZY, Jourdan M, Klein B, Brailly H, Brochier J: Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies. Eur Cytokine Netw 5:293, 1994
19. Gu ZJ, Wijdenes J, Zhang XG, Hallet MM, Clement C, Klein B: Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6. interleukin-11, leukemia inhibitory factor or oncostatin M, J Immunol Methods 190:21, 1996
20. Liautard J, Sun RX, Cotte N, Gaillard JP, Mani JC, Klein B, Brochier J: Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor. Cytokine 9:233, 1997
21. Sun RX, Lu ZY, Wijdenes J, Brochier J, Hertog C, Rossi JF, Klein B: Large scale and clinical grade purification of syndecan-l + malignant plasma cells. J Immunol Methods 205:73, 1997
22. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM: A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94:318, 1996
23. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654, 1994
24. Klein B, Zhang XG, Rossi JF: Cytokine, cytokine receptors and signal transduction in human multiple myeloma, in Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds): Myeloma, Biology and Management. Oxford, UK. Oxford, 1998, p 70
25. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B: Measurement of whole body interleukin-6 (IL-6) production: Prediction of the efficacy of anti-IL-6 treatments. Blood 86:3123, 1995
26. Bonfil RD, Vinyals A, Bustuoabad OD, Llorens A, Benavides FJ, Gonzalez-Garrigues M, Fabra A: Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int J Cancer 58:233. 1994
27. Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B: IFN-alpha induced autocrine production of IL-6 in myeloma cell lines. J Immunol 147:4402, 1991
28. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of cytokines and gp 130. Blood 86:1243, 1995
29. Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23:820, 1993
30. Gaillard JP, Liautard J, Klein B, Brochier J: Major role of the soluble interleukin-6/interleukin-6R complex for the proliferation of interleukin-6-dependent human myeloma cell lines. Eur J Immunol 27:3332, 1997
31. Van Riet I, De Greef C, Anarchi F, Woischwill C, De Waele M, Bakkus M, Lacor P, Schots R, Van Camp B: Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Leukemia 11:284, 1997
32. Zhang XG, Klein B, Bataille R: Interleukin-6 is a potent myeloma-cell growth factor in patients with agressive multiple myeloma. Blood 74:11, 1989
33. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260, 1997
34. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9:321, 1995
35. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KC: Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gam m a in multiple myeloma cells. Blood 90:279, 1997
36. Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP, Schlossman RL, Anderson KC: MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 90:1982, 1997
37. Tasaka T, Berenson J, Vescio R, Hirama T, Miller CW, Nagai M, Takahara J, Koeffler HP: Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. Br J Haematol 96:98, 1997
38. Zandecki M, Facon T, Preudhomme C, Vanrumbeke M, Vachee A, Quesnel B, Lai JL, Cosson A, Fenaux P: The retinoblastoma gene (RB-1) status in multiple myeloma: A report on 35 cases. Leuk Lymphoma 18:497, 1995
39. Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadoro M: Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8:758, 1994
40. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C: p53 and RAS gene mutations in multiple myeloma. Oncogene 7:2539, 1992
41. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128, 1993
42. Raynaud SD, Bekri S, Leroux D, Grosgeorge J, Klein B, Bastard C, Gaudray P, Simon MP: Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chromosom Cancer 8:80, 1993
43. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM: Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88:674, 1996
44. lida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, Chaganti RS, Dalla-Favera R: Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17:226, 1997
45. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645, 1996
46. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic effects of antiinterleukin-6 (IL-6) murine monoclonal antibody in advanced multiple myeloma. Blood 86:685, 1995
47. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1198, 1991
48. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B: Alleviation of systemic manifestations of Castlemans disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602, 1994
49. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M, Bone F, Galanaud P: Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms. Blood 84:2472, 1994